DK1119371T3 - Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi - Google Patents

Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi

Info

Publication number: DK1119371T3
Authority: DK; Denmark
Prior art keywords: flt4; vegfr; target; tumor imaging; antitumor therapy
Prior art date: 1998-10-09

Application number

DK99956525.2T

Other languages

English (en)

Inventor

Kari Alitalo

Arja Kaipainen

Reija Valltola

Lotta Jussila

Original Assignee

Vegenics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-09

Filing date

1999-10-08

Publication date

2011-03-07

1998-10-09 Priority claimed from US09/169,079 external-priority patent/US6824777B1/en

1999-10-08 Application filed by Vegenics Ltd filed Critical Vegenics Ltd

2011-03-07 Application granted granted Critical

2011-03-07 Publication of DK1119371T3 publication Critical patent/DK1119371T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Mycology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pathology (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK99956525.2T 1998-10-09 1999-10-08 Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi DK1119371T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/169,079 US6824777B1 (en)	1992-10-09	1998-10-09	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
PCT/US1999/023525 WO2000021560A1 (en)	1998-10-09	1999-10-08	Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY

Publications (1)

Publication Number	Publication Date
DK1119371T3 true DK1119371T3 (da)	2011-03-07

Family

ID=22614189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99956525.2T DK1119371T3 (da)	1998-10-09	1999-10-08	Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi

Country Status (13)

Country	Link
US (4)	US8444957B2 (da)
EP (1)	EP1119371B1 (da)
JP (5)	JP4841724B2 (da)
CN (1)	CN100340291C (da)
AT (1)	ATE489108T1 (da)
AU (2)	AU774266B2 (da)
CA (1)	CA2345276C (da)
DE (1)	DE69942981D1 (da)
DK (1)	DK1119371T3 (da)
ES (1)	ES2357406T3 (da)
NO (1)	NO20011759L (da)
NZ (2)	NZ529063A (da)
WO (1)	WO2000021560A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6818220B1 (en)	1994-11-14	2004-11-16	Licentia Ltd.	Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en)	1995-08-01	2008-09-09	Vegenics Limited	Antibodies to VEGF-C
US6361946B1 (en)	1997-02-05	2002-03-26	Licentia Ltd	Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
CA2231400A1 (en)	1995-09-08	1997-03-13	Genentech, Inc.	Vegf-related protein
US7125714B2 (en)	1997-02-05	2006-10-24	Licentia Ltd.	Progenitor cell materials and methods
WO2000021560A1 (en) *	1998-10-09	2000-04-20	Ludwig Institute For Cancer Research	Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
US7223724B1 (en)	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
EP1553414A1 (en) *	1999-04-13	2005-07-13	Medarex, Inc.	Methods for the diagnosis and treatment of metastatic prostate tumors
DE60131146T2 (de)	2000-02-25	2008-03-06	Ludwig Institute For Cancer Research	Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
WO2002011769A1 (en)	2000-08-04	2002-02-14	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7611711B2 (en)	2001-01-17	2009-11-03	Vegenics Limited	VEGFR-3 inhibitor materials and methods
CA2435503C (en)	2001-01-19	2011-02-22	Ludwig Institute For Cancer Research	Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
EP2228389B1 (en)	2001-04-13	2015-07-08	Human Genome Sciences, Inc.	Antibodies against vascular endothelial growth factor 2
US7109165B2 (en)	2001-05-18	2006-09-19	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2005078097A2 (en)	2004-02-10	2005-08-25	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
US20040242851A1 (en) *	2001-06-26	2004-12-02	Zhenping Zhu	Bispecific antibodies that bind to vegf receptors
US20030113324A1 (en) *	2001-10-01	2003-06-19	Kari Alitalo	Neuropilin/VEGF-C/VEGFR-3 materials and methods
EP1432724A4 (en) *	2002-02-20	2006-02-01	Sirna Therapeutics Inc	INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8003613B2 (en)	2003-11-17	2011-08-23	University Of Florida Research Foundation, Inc.	Methods and compositions for inducing apoptosis
WO2005087177A2 (en)	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
AU2006279462A1 (en)	2005-08-15	2007-02-22	Vegenics Limited	Modified VEGF and PDGF with improved angiogenic properties
US7629125B2 (en)	2006-11-16	2009-12-08	General Electric Company	Sequential analysis of biological samples
US8305579B2 (en)	2006-11-16	2012-11-06	Thomas Pirrie Treynor	Sequential analysis of biological samples
US9201063B2 (en)	2006-11-16	2015-12-01	General Electric Company	Sequential analysis of biological samples
US9677125B2 (en)	2009-10-21	2017-06-13	General Electric Company	Detection of plurality of targets in biological samples
WO2011106697A1 (en)	2010-02-25	2011-09-01	Schepens Eye Research Institute	Therapeutic compositions for the treatment of dry eye disease
ES2663009T3 (es)	2010-10-29	2018-04-10	Sirna Therapeutics, Inc.	Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2014064203A1 (en)	2012-10-26	2014-05-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
US9745558B2 (en)	2013-02-18	2017-08-29	Vegenics Pty Limited	VEGFR-3 ligand binding molecules and uses thereof
US10274503B2 (en)	2013-05-08	2019-04-30	Vegenics Pty Limited	Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
KR102131370B1 (ko)	2013-10-18	2020-07-08	삼성전자주식회사	Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CN114262683B (zh) *	2022-03-01	2022-06-17	中国科学院动物研究所	一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4652639A (en)	1982-05-06	1987-03-24	Amgen	Manufacture and expression of structural genes
US4543439A (en)	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
DE3587657D1 (de)	1984-01-30	1993-12-23	Imp Cancer Res Tech	Verbesserungen an wachstumsfaktoren.
HU205266B (en)	1987-03-11	1992-04-28	Erba Carlo Spa	Process for producing immunglobuline conjugates
DE68926888T2 (de)	1988-01-22	1997-01-09	Zymogenetics Inc	Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5198359A (en)	1989-03-07	1993-03-30	Boehringer Ingelheim International Gmbh	Recombinant protein receptor for il-2
ES2057571T3 (es)	1989-05-22	1994-10-16	Zymogenetics Inc	Receptor de pdgf-alfa.
US5183884A (en)	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
DK0584082T3 (da)	1991-01-31	2000-10-16	Univ California	Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
US5256766A (en)	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals
EP0536350B1 (en)	1991-02-22	2002-08-07	American Cyanamid Company	Identification of a novel human receptor tyrosine kinase gene
US5231001A (en)	1991-03-14	1993-07-27	The United States Of America As Represented By The Department Of Health And Human Services	Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5367057A (en)	1991-04-02	1994-11-22	The Trustees Of Princeton University	Tyrosine kinase receptor flk-2 and fragments thereof
US5270458A (en)	1991-04-02	1993-12-14	The Trustees Of Princeton University	Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5185438A (en)	1991-04-02	1993-02-09	The Trustees Of Princeton University	Nucleic acids encoding hencatoporetic stem cell receptor flk-2
AU669124B2 (en)	1991-09-18	1996-05-30	Kyowa Hakko Kirin Co., Ltd.	Process for producing humanized chimera antibody
AU3353293A (en)	1992-01-09	1993-08-03	Helsinki University Holding, Ltd.	Tie, a novel endothelial cell receptor tyrosine kinase
CA2128722A1 (en)	1992-01-22	1993-08-05	William I. Wood	Novel protein tyrosine kinases
US6331302B1 (en)	1992-01-22	2001-12-18	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
US5635177A (en)	1992-01-22	1997-06-03	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
US5660827A (en)	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
US6824777B1 (en)	1992-10-09	2004-11-30	Licentia Ltd.	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en)	1992-10-09	1998-07-07	Helsinki University Licensing, Ltd.	FLT4, a receptor tyrosine kinase
HU221343B1 (en)	1992-10-28	2002-09-28	Genentech Inc	Use of anti-vegf antibodies for the treatment of cancer
US5712395A (en)	1992-11-13	1998-01-27	Yissum Research Development Corp.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en)	1992-11-13	1998-06-09	Sugen, Inc.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de)	1993-10-30	1994-08-25	Biotest Pharma Gmbh	Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
CA2184584C (en)	1994-03-08	2003-04-08	Jing-Shan Hu	Vascular endothelial growth factor 2
GB9410534D0 (en) *	1994-05-26	1994-07-13	Lynxvale Ltd	Improvements in or relating to growth factor inhibitors
FI964862L (fi) *	1994-06-09	1997-02-10	Kari Alitalo	FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa
US5763733A (en)	1994-10-13	1998-06-09	Enzon, Inc.	Antigen-binding fusion proteins
US6645933B1 (en)	1995-08-01	2003-11-11	Helsinki University Licensing Ltd. Oy	Receptor ligand VEGF-C
WO1998033917A1 (en)	1994-11-14	1998-08-06	The Ludwig Institute For Cancer Research	Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
CA2231400A1 (en)	1995-09-08	1997-03-13	Genentech, Inc.	Vegf-related protein
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU3968597A (en) *	1996-08-02	1998-02-25	Children's Medical Center Corporation	Method of regulating the female reproductive system through angiogenesis inhibitors
DK2107109T3 (da)	1996-08-23	2012-09-24	Vegenics Pty Ltd	Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)
KR100628697B1 (ko)	1997-12-24	2006-09-28	루드빅 인스티튜트 포 캔서 리서치	맥관 내피 성장인자 ｄ를 발현하는 발현 벡터와 셀라인,및 흑색종을 치료하는 방법
WO2000021560A1 (en) *	1998-10-09	2000-04-20	Ludwig Institute For Cancer Research	Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
KR101681886B1 (ko)	2015-04-06	2016-12-12	서울대학교산학협력단	지르코니아 결합능을 가지는 펩타이드

1999
- 1999-10-08 WO PCT/US1999/023525 patent/WO2000021560A1/en not_active Ceased
- 1999-10-08 CA CA2345276A patent/CA2345276C/en not_active Expired - Fee Related
- 1999-10-08 JP JP2000575533A patent/JP4841724B2/ja not_active Expired - Fee Related
- 1999-10-08 DK DK99956525.2T patent/DK1119371T3/da active
- 1999-10-08 CN CNB998142859A patent/CN100340291C/zh not_active Expired - Fee Related
- 1999-10-08 NZ NZ529063A patent/NZ529063A/en unknown
- 1999-10-08 NZ NZ511408A patent/NZ511408A/en unknown
- 1999-10-08 ES ES99956525T patent/ES2357406T3/es not_active Expired - Lifetime
- 1999-10-08 AT AT99956525T patent/ATE489108T1/de active
- 1999-10-08 DE DE69942981T patent/DE69942981D1/de not_active Expired - Lifetime
- 1999-10-08 EP EP99956525A patent/EP1119371B1/en not_active Expired - Lifetime
- 1999-10-08 AU AU13121/00A patent/AU774266B2/en not_active Ceased
2001
- 2001-04-06 NO NO20011759A patent/NO20011759L/no unknown
2004
- 2004-09-03 AU AU2004208675A patent/AU2004208675B2/en not_active Ceased
2010
- 2010-02-17 US US12/707,423 patent/US8444957B2/en not_active Expired - Fee Related
2011
- 2011-01-04 JP JP2011000273A patent/JP5784310B2/ja not_active Expired - Lifetime
- 2011-08-17 JP JP2011178553A patent/JP5642637B2/ja not_active Expired - Fee Related
2013
- 2013-04-18 US US13/865,711 patent/US20140072511A1/en not_active Abandoned
- 2013-05-07 JP JP2013097900A patent/JP2013209382A/ja active Pending
2014
- 2014-10-01 US US14/504,028 patent/US20150158928A1/en not_active Abandoned
2015
- 2015-04-06 JP JP2015077656A patent/JP2015157829A/ja active Pending
- 2015-12-29 US US14/982,422 patent/US20160184405A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1119371B1 (en)	2010-11-24
WO2000021560A9 (en)	2000-09-21
JP2015157829A (ja)	2015-09-03
DE69942981D1 (de)	2011-01-05
US20160184405A1 (en)	2016-06-30
JP5642637B2 (ja)	2014-12-17
AU774266B2 (en)	2004-06-24
US20150158928A1 (en)	2015-06-11
AU2004208675B2 (en)	2006-03-02
WO2000021560A1 (en)	2000-04-20
AU2004208675A1 (en)	2004-09-30
NZ529063A (en)	2005-07-29
ATE489108T1 (de)	2010-12-15
CN1329504A (zh)	2002-01-02
JP2002527404A (ja)	2002-08-27
JP2011121957A (ja)	2011-06-23
JP5784310B2 (ja)	2015-09-24
JP4841724B2 (ja)	2011-12-21
US20140072511A1 (en)	2014-03-13
ES2357406T3 (es)	2011-04-26
NO20011759L (no)	2001-06-11
NZ511408A (en)	2004-04-30
US8444957B2 (en)	2013-05-21
US20100278736A1 (en)	2010-11-04
EP1119371A1 (en)	2001-08-01
JP2013209382A (ja)	2013-10-10
CA2345276A1 (en)	2000-04-20
NO20011759D0 (no)	2001-04-06
CA2345276C (en)	2011-03-29
AU1312100A (en)	2000-05-01
JP2012019790A (ja)	2012-02-02
CN100340291C (zh)	2007-10-03

Publication	Publication Date	Title
DK1119371T3 (da)	2011-03-07	Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
NO20033285D0 (no)	2003-07-21	FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi
EP1141286A4 (en)	2002-06-26	Cytokine receptor chain
GB9810276D0 (en)	1998-07-15	Novel compounds
NO20002777L (no)	2000-06-02	FremgangsmÕte for bekjempelse av fedme
PL345793A1 (en)	2002-01-02	Neisseria meningitidis
GB9820003D0 (en)	1998-11-04	Novel compounds
DE69718146D1 (de)	2003-02-06	At1 rezeptor antagonist zur anregung von apoptosis
DK1078064T3 (da)	2006-01-02	Forbindelser fra moraxella catarrhalis
GB9812440D0 (en)	1998-08-05	Novel compounds
AU4504999A (en)	1999-12-30	Novel compounds
DK1326982T3 (da)	2008-09-29	BASB205-polypeptider og polynukleotider kodende derfor
AU4567300A (en)	2000-12-12	Novel compounds
GB9918208D0 (en)	1999-10-06	Novel compounds
GB0025170D0 (en)	2000-11-29	Novel compounds
GB9918302D0 (en)	1999-10-06	Novel compounds
AU6832300A (en)	2001-02-19	Novel compounds
GB9918206D0 (en)	1999-10-06	Novel compounds
GB0025169D0 (en)	2000-11-29	Novel compounds
GB9918281D0 (en)	1999-10-06	Novel compounds
GB9914945D0 (en)	1999-08-25	Novel compounds
AU1383901A (en)	2001-04-17	Novel compounds
BR1100558A (pt)	2008-05-06	famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer.
MX9605355A (es)	1997-10-31	El uso de antagonistas de receptor nk-1 para preparar composiciones para tratar cancer.